DOCSLIB.ORG

How Are Odontogenic Infections Best Managed?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
How Are Odontogenic Infections Best Managed? ––––––– Point of Care ––––– For patients with “stable” cardiac disease, it is THE AUTHOR still prudent to administer a minimal amount of epinephrine while always avoiding intravascular Dr. Ben Davis is associate professor in the depart- injections. Although pain control is of paramount ment of oral and maxillofacial sciences and head of the division of oral and maxillofacial surgery, importance, the potentially deleterious effect of Dalhousie University, Halifax, Nova Scotia. epinephrine can be minimized by limiting the Email: [email protected] amount to 40 μg. There is no evidence to support References exceeding this dose for such patients. This amount 1. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, is contained in 2 cartridges of 1:100 000 or 4 car- Fleishmann KE, et al. 2009 ACCF/AHA focused update on periopera- tive beta blockade incorporated into the ACC/AHA 2007 guidelines tridges of 1:200 000 (there is little benefit from on perioperative cardiovascular evaluation and care for noncardiac using the 1:100 000 concentration of epinephrine surgery: a report of the American college of cardiology founda- 3 tion/American heart association task force on practice guidelines. for routine dentistry). Although the half life of Circulation. 2009;120(21):e169-276. Epub 2009 Nov 2. epinephrine is short, exceeding 40 μg epinephrine 2. Pharmacology of vasoconstrictors. In: Malamed SF, editor. Handbook of local anesthesia. 5th ed. St. Louis: Elsevier Mosby; per appointment cannot be recommended unless 2004. p. 41-54. the patient’s cardiac status is monitored continu- 3. Becker DE, Reed KL. Essentials of local anesthetic pharmacology. ously during the procedure. a Anesth Prog. 2006;53(3):98-108. Cite this as: QUESTION 3 J Can Dent Assoc 2010;76:a37 How are odontogenic infections best managed? Background anaerobic bacteria and only 6% by aerobic bac- ental infections, including gingivitis, peri- teria alone.1 The most common species of bacteria odontitis, dental caries and odontogenic isolated in odontogenic infections are the anaer- Dinfections, result in numerous dental visits obic gram-positive cocci Streptococcus milleri each year in Canada. They can range in severity group and Peptostreptococcus.2 Anaerobic gram- from a mild buccal space infection to a severe negative rods, such as Bacteroides (Prevotella) also life-threatening multi-space infection. All dentists play an important role. Anaerobic gram-negative should be comfortable with prompt diagnosis and cocci and anaerobic gram-positive rods have little management of these types of infections. This re- effect.2 view of odontogenic infections describes causative Odontogenic infections progress through 3 organisms, management including appropriate 3 antibiotic selection and the indications for referral stages: inoculation, cellulitis and abscess (Table 1). to a specialist. Bacteria gain entrance to the surrounding facial Most odontogenic infections are caused by spaces by direct extension from the periapical re- more than 1 species of the bacteria normally found gion of the involved tooth. The pattern of spread is within the oral cavity. Roughly 50% of odonto- predictable depending on the relationship between genic infections are caused by anaerobic bac- the point of attachment of the adjacent muscle and teria alone, 44% by a combination of aerobic and the tooth apex.4 Table 1 Characteristics of the 3 stages of infection Characteristic Inoculation Cellulitis Abscess Duration (days) 0–3 2–5 4–10 Discomfort Mild Severe, diffuse Mild, localized Palpation Soft, doughy Firm, indurated Fluctuant, tender Pus None None Present Skin Normal Red Red periphery Severity Minimal Greater Less Bacterial species Aerobic Mixed Anaerobic 114 JCDA • www.jcda.ca • 2010 • Vol. 76, No. 2 • ––––––– Point of Care ––––– Table 2 Antibiotics commonly prescribed for odontogenic infections5 Antibiotic Usual adult dosage Usual pediatric dosage Penicillin V 600 mg every 6 h 25–50 mg/kg/day divided into 4 doses Amoxicillin 500 mg every 8 h 25–50 mg/kg/day divided into 4 doses Cephalexin 500 mg every 6 h 25–50 mg/kg/day divided into 4 doses 2 g 1 h pre-op (joint prophylaxis) Metronidazole 500 mg twice daily 15–30 mg/kg/day divided into 3 doses Clindamycin 300–450 mg every 6 h 10–30 mg/kg/day divided into 3 or 4 doses Moxifloxacin 400 mg daily Not established Erythromycin 500 mg enteric coated every 8 h 30–50 mg/kg/day divided into 2–4 doses 333 mg enteric coated every 6 h 250 mg (base) every 6 h Treatment of odontogenic infections includes Beta Lactam Antibiotics diagnosis and management of the causative factor Penicillins: Penicillins are considered the first and, usually, prescription of appropriate anti- line of treatment for odontogenic infections. They biotics. It is imperative that the source of infection produce their effect by inhibiting cross-linking in be addressed immediately. Placing a patient on the bacterial cell wall and are, thus, bactericidal. antibiotics and rescheduling to have the source They have a fairly narrow antimicrobial spectrum, dealt with at a later time is not sound practice, but cover most bacteria associated with odonto- as most often the infection will worsen. In genic infections. Penicillin resistance has been re- addition, the patient’s medical status must ported recently.6 This occurs primarily through the be optimized. The patient’s fluid and nutrition production of beta lactamase. Evidence suggests status should also be addressed, as many patients a high incidence of penicillin resistance among with odontogenic infections have decreased oral patients previously treated with beta lactam anti- intake due to pain and difficulty in chewing or biotics in in vitro studies.7 swallowing. In culture and sensitivity testing on 94 patients The decision to place the patient on antibiotics with odontogenic abscesses, penicillin V was the depends on the location and severity of the infec- least effective antibiotic for eradicating bacterial tion and the patient’s medical conditions. A mild isolates.7 Despite this, more than 95% of patients vestibular space infection may not require anti- treated with surgical incision and drainage in con- biotics after the offending tooth has been removed. junction with penicillin V recovered satisfactorily. However, more serious infections do require The discord between in vitro testing and clin- appropriate antibiotics. The clinician must be ical response was thought to be due to the sus- aware of the most likely causative organisms and ceptibility to penicillin of the dominant causative prescribe the narrowest spectrum of antibiotics strains of bacteria isolated from the abscesses. that will cover all possible offending organisms. Amoxicillin has a broader spectrum of activity Table 2 lists the antibiotics most commonly used than penicillin V, but does not provide any better to treat odontogenic infections and their usual coverage in treating odontogenic infections. Its oral adult and pediatric dosages.5 Antibiotics are dosing schedule and ability to be taken with food typically prescribed for 7 days or until 3 days after may make it more acceptable for patients, resulting symptoms have resolved. in better compliance. Severe infections must be identified and re- ferred to a specialist in a timely manner. The signs Cephalosporins: The mechanism of action of ceph- and symptoms of a severe infection are fever (tem- alosporins is similar to that of penicillins. There perature > 38°C), stridor, odynophagia, rapid pro- are 4 generations of cephalosporins; their spec- gression and the involvement of multiple spaces trum of antibacterial coverage, especially against and secondary anatomic spaces.3 The presence of gram-negative bacteria, generally increases from any of these warrants referral to an oral and max- the first to the fourth generation. The reported in- illofacial surgeon. cidence of cross-reactivity with penicillin is about JCDA • www.jcda.ca • 2010 • Vol. 76, No. 2 • 115 ––––––– Point of Care ––––– 7%–18%,8 which should be considered when a pa- trum of activity similar to that of penicillin V. tient reports an allergy to penicillin. Like penicillin-resistance, resistance to erythro- Cephalosporins are not a first-line treatment mycin has become a clinical concern. Kuriyama in the management of odontogenic infections. and colleagues10 found that erythromycin was in- Cephalexin is more commonly used for sinus com- effective against Streptococcus viridans and most munications and for antibiotic prophylaxis in pa- Fusobacterium species. Thus, erythromycin should tients with prosthetic joints. be considered a historical antibiotic in the man- agement of odontogenic infections. Metronidazole: Metronidazole is a synthetic anti- biotic that is effective against anaerobic bacteria. Conclusion It disrupts bacterial DNA, thus inhibiting nucleic Odontogenic infections are polymicrobial in acid synthesis. It provides excellent anaerobic nature. Prompt diagnosis and treatment, including coverage and should be used in conjunction with elimination of the causative factor, are crucial to penicillin. their successful management. Antibiotics are a Clindamycin: Clindamycin inhibits bacterial useful adjunct in the treatment of odontogenic protein synthesis and is bactericidal at high dos- infections, but should not replace removal of the ages. Its use has increased in recent years due causative factor. All dentists should know when to increasing concern over penicillin resistance. referral to a specialist is warranted. For example, it has replaced penicillin
Load more

Recommended publications
  • (Ie Bacteria).The Term Is Used for Both Treatment of Cancer and Treatment of Infection
    BASIC PRINCIPLES OF ANTIMICROBIAL THERAPY • Chemotherapy = the use of chemicals against invading organisms (ie bacteria).The term is used for both treatment of cancer and treatment of infection. • Antibiotic = a chemical that is produced by one microorganism and has the ability to harm other microbes. • Selective toxicity = the ability of a drug to injure a target cell or organism without injuring other cells or organisms that are in intimate contact . CLASSIFICATION OF ANTIMICROBIAL DRUGS BY SUSCEPTIBLE ORGANISMS • 1) Antibacterial drugs (narrow and broad spectrum).Examples: Penicillin G, erythromycin,cephalosporins,sulfonamides • • 2) Antiviral drugs (examples:acyclovir,amantadine) • 3) Antifungal drugs • (examples : amphotericin,ketoconazole) 1 CLASSIFICATION BY MECHANISM OF ACTION • 1) Drugs that inhibit bacterial wall synthesis or activate enzymes that disrupt the cell wall. • 2) Drugs that increase cell membrane permeability (causing leakage of intracellular material) • 3) Drugs that cause lethal inhibition of bacterial protein synthesis. • 4) Drugs that cause nonlethal inhibition of protein synthesis (bacteriostatics). • 5) Drugs that inhibit bacterial synthesis of nucleic acids • 6) Antimetabolites (disruption of specific biochemichal reactions-->decrease in the synthesis of essential cell constituents). • 7) Inhibitors of viral enzymes. • Acquired resistance to Antimicrobial drugs. • Mechanisms: • 1) Microbes may elaborate drug-metabolizing enzymes (ie penicillinase). 2 • 2) Microbes may cease active uptake of certain drugs • 3) Microbial drug receptors may undergo change resulting in decreased antibiotic binding and action. • 4) Microbes may synthesize compounds that antagonize drug actions. • How is resistance acquired? • A) Spontaneous mutation • B) Conjugation • Use of antibiotics PROMOTES the emergence of drug-resistant microbes. • Suprainfection (or supeinfection) : a new infection that appears through the course of treatment for a primary infection.
    [Show full text]
  • Antimicrobial Agents David S
    University of Montana ScholarWorks at University of Montana Syllabi Course Syllabi Spring 1-2003 PHAR 328.01: Antimicrobial Agents David S. Freeman University of Montana - Missoula Let us know how access to this document benefits ouy . Follow this and additional works at: https://scholarworks.umt.edu/syllabi Recommended Citation Freeman, David S., "PHAR 328.01: Antimicrobial Agents" (2003). Syllabi. 4290. https://scholarworks.umt.edu/syllabi/4290 This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. PHARMACY 328 (ANTIMICROBIAL AGENTS) SPRING SEMESTER, 2003 INSTRUCTOR: David Freeman, Office - SB 308 Office Phone: 243-4772 Home Phone: 728-6551 E-mail: [email protected] EXAMS AND GRADING: First Exam: Tuesday, MARCH 4 50 points Second Exam: Thursday, APRIL 3 70 points Third Exam: Thursday, MAY 1 80 points Final Exam: 100 points 10 Point Quizzes: Best 5 or 6 out of 6 scores . 50 or 60 points Total Points: 350, or 360 90-100% = A 80-89 % = B 70-79 % = C 65-69 % = D * All EXAMS are comprehensive * All exams and quizzes must be taken at scheduled times * Instructor must be informed BEFORE missing a scheduled exam period and MUST be based on GOOD REASONS * Missed exam periods must be made up within 2 days * No make up quizzes STUDENT PERFORMANCE OBJECTIVES: 1) Know the normal relevant biochemical
    [Show full text]
  • Prophylactic Use of Antibiotics in Dentistry
    VIDENSKAB OG KLINIK | Oversigtsartikel ABSTRACT Prophylactic use Antibiotic prophylaxis can prevent the develop- of antibiotics in ment of either systemic or local infectious dentistry complications Riina Richardson, lecturer in oral medicine and Senior Clinical Re- The indications for the use of antimicrobials in search Fellow and Honorary Consultant in Infectious Diseases, dentistry are (i) treatment of acute infection and Adjunct Professor, DDS, PhD, FRCPath, Institute of Dentistry, Univer- sity of Helsinki, Finland, Department of Oral and Maxillofacial Disea- (ii) prophylaxis against infection (single-dose ses, Helsinki University Hospital, Finland, and Manchester Academic prophylaxis and perioperative prophylaxis). An- Health Science Centre, School of Translational Medicine, University of Manchester and University Hospital of South Manchester, United tibiotic prophylaxis refers to the administration Kingdom of antimicrobials in situations where there is no Elina Ketovainio, DDS, Institute of Dentistry, University of Helsinki, actual infection, but where the risk of infection Finland and Department of Oral and Maxillofacial Diseases, Helsinki is substantial, for example, in the case of inva- University Hospital, Finland sive procedures at contaminated sites. The Asko Järvinen, head of Department, adjunct Professor, MD, PhD, spe- aim of antibiotic prophylaxis is to prevent the cialist in internal medicine, infectious diseases and clinical pharma- development of either systemic or local infec- cology, Department of medicine, Clinic of Infectious Diseases, Hel- sinki University Hospital, Aurora Hospital, Helsinki, Finland tion complications. Severe underlying diseases including immunosuppressive illnesses and their treatment have been shown to predispose the patient to systemic odontogenic infections. he indications for antimicrobials in dentistry are treat- Manipulation of infected oral tissues, such as ment of acute infection and infection prophylaxis (sin- measurement of periodontal pockets, calculus T gle-dose prophylaxis and perioperative prophylaxis).
    [Show full text]
  • History of Antimicrobial Agents and Resistant Bacteria
    Research and Reviews History of Antimicrobial Agents and Resistant Bacteria JMAJ 52(2): 103–108, 2009 Tomoo SAGA,*1 Keizo YAMAGUCHI*2 Abstract Antimicrobial chemotherapy has conferred huge benefits on human health. A variety of microorganisms were elucidated to cause infectious diseases in the latter half of the 19th century. Thereafter, antimicrobial chemo- therapy made remarkable advances during the 20th century, resulting in the overly optimistic view that infectious diseases would be conquered in the near future. However, in response to the development of antimicrobial agents, microorganisms that have acquired resistance to drugs through a variety of mechanisms have emerged and continue to plague human beings. In Japan, as in other countries, infectious diseases caused by drug- resistant bacteria are one of the most important problems in daily clinical practice. In the current situation, where multidrug-resistant bacteria have spread widely, options for treatment with antimicrobial agents are limited, and the number of brand new drugs placed on the market is decreasing. Since drug-resistant bacteria have been selected by the use of antimicrobial drugs, the proper use of currently available antimicrobial drugs, as well as efforts to minimize the transmission and spread of resistant bacteria through appropriate infection control, would be the first step in resolving the issue of resistant organisms. Key words Antimicrobial agents, Resistant bacteria, History not achieve beneficial effect, and moreover, Introduction may lead to a worse prognosis. In addition, in a situation where multidrug-resistant organisms Antimicrobial drugs have caused a dramatic have spread widely, there may be quite a limited change not only of the treatment of infectious choice of agents for antimicrobial therapy.
    [Show full text]
  • Antimicrobials and Resistance | Microbiology and Risk Factors for Transmission | Table of Contents | APIC
    11/2/2017 26. Antimicrobials and Resistance | Microbiology and Risk Factors for Transmission | Table of Contents | APIC Antimicrobials and Resistance Author(s): Forest W. Arnold, DO, MSc, FIDSA Assistant Professor, Division of Infectious Diseases University of Louisville Hospital Epidemiologist University of Louisville Hospital Louisville, KY Published: November 1, 2017 Abstract Although infection prevention traditionally has approached the problem of resistance primarily from the aspect of preventing transmission from an infected patient to a noninfected patient, more needs to be done to improve how antimicrobials are commonly used. Antimicrobial use is the main selective pressure responsible for the increasing resistance seen in hospitals. Patients come to possess a resistant pathogen either by transmitting bacteria that already have the resistance gene in place or by having their bacteria acquire a gene that codes for resistance. The former is more common because it merely requires a handshake while the latter takes days to weeks to develop. To have an impact on antimicrobial use so as to reduce resistance, infection preventionists (IPs) need a working knowledge of available antimicrobials, principles for their appropriate use, the mechanisms by which these drugs inhibit microbial growth, and the mechanisms by which microorganisms develop resistance. In addition, IPs need to understand promising new strategies to improve antimicrobial use and how members of the infection prevention community can become more involved. Key Concepts Although infection prevention traditionally has approached the problem of resistance primarily from the aspect of preventing transmission, more needs to be done to control how antimicrobials are commonly used. Antimicrobial stewardship is the best investment for preventing the proliferation of multidrug-resistant pathogens and the adverse events associated with the drugs used to treat such pathogens.
    [Show full text]
  • De-Escalation of Empirical Therapy Is Associated with Lower Mortality In
    Intensive Care Med (2014) 40:32–40 DOI 10.1007/s00134-013-3077-7 ORIGINAL ARTICLE J. Garnacho-Montero De-escalation of empirical therapy is A. Gutie´rrez-Pizarraya A. Escoresca-Ortega associated with lower mortality in patients Y. Corcia-Palomo Esperanza Ferna´ndez-Delgado with severe sepsis and septic shock I. Herrera-Melero C. Ortiz-Leyba J. A. Ma´rquez-Va´caro J. Garnacho-Montero Á C. Ortiz-Leyba septic shock at ICU admission were Received: 1 July 2013 Instituto de Biomedicina de Accepted: 10 August 2013 treated empirically with broad-spec- Sevilla (IBIS), Hospital Universitario Published online: 12 September 2013 trum antibiotics. Of these, 628 were Ó Springer-Verlag Berlin Heidelberg and Virgen del Rocı´o/CSIC/Universidad de Sevilla, Sevilla, Spain evaluated (84 died before cultures ESICM 2013 were available). De-escalation was Electronic supplementary material J. Garnacho-Montero Á applied in 219 patients (34.9 %). By The online version of this article A. Gutie´rrez-Pizarraya Á C. Ortiz-Leyba multivariate analysis, factors inde- (doi:10.1007/s00134-013-3077-7) contains Spanish Network for Research in pendently associated with in-hospital supplementary material, which is available Infectious Disease (REIPI), to authorized users. mortality were septic shock, SOFA Hospital Universitario Virgen del score the day of culture results, and Rocı´o, Sevilla, Spain inadequate empirical antimicrobial A. Gutie´rrez-Pizarraya therapy, whereas de-escalation ther- e-mail: [email protected] apy was a protective factor [Odds- Ratio (OR) 0.58; 95 % confidence A. Gutie´rrez-Pizarraya Unidad Clı´nica de Enfermedades interval (CI) 0.36–0.93).
    [Show full text]
  • Disinfection 101
    Disinfection 101 Last Modified: May 2008 Author: Glenda Dvorak, DVM, MS, MPH Portions Reviewed By: James Roth, DVM, PhD, DACVM; Sandra Amass, DVM, PhD, DABVP Center for Food Security and Public Health 2160 Veterinary Medicine Ames, IA 50011 515-294-7189 www.cfsph.iastate.edu Disinfection 101 TABLE OF CONTENTS Introduction......................................................................................................................... 3 Disinfectants Defined............................................................................................................ 3 Disinfectant Labels ............................................................................................................... 4 Label Claims ................................................................................................................................ 4 Other Important Information on a Product Label............................................................................. 5 Considerations and assessment for a disinfection action plan .................................................. 5 Microorganism considerations........................................................................................................ 5 Disinfectant considerations............................................................................................................ 6 Environmental considerations ........................................................................................................ 7 Physical Disinfection ....................................................................................................................
    [Show full text]
  • National Treatment Guidelines for Antimicrobial Use in Infectious Diseases
    National Treatment Guidelines for Antimicrobial Use in Infectious Diseases Version 1.0 (2016) NATIONAL CENTRE FOR DISEASE CONTROL Directorate General of Health Services Ministry of Health & Family Welfare Government of India CONTENTS Chapter 1 .................................................................................................................................................................................................................. 7 Introduction ........................................................................................................................................................................................................ 7 Chapter 2. ................................................................................................................................................................................................................. 9 Syndromic Approach For Empirical Therapy Of Common Infections.......................................................................................................... 9 A. Gastrointestinal & Intra-Abdominal Infections ......................................................................................................................................... 10 B. Central Nervous System Infections ........................................................................................................................................................... 13 C. Cardiovascular Infections .........................................................................................................................................................................
    [Show full text]
  • Chlorhexidine: a Multi-Functional Antimicrobial Drug a Peer-Reviewed Publication Written by Gary J
    Earn 4 CE credits This course was written for dentists, dental hygienists, and assistants. Chlorhexidine: A Multi-Functional Antimicrobial Drug A Peer-Reviewed Publication Written by Gary J. Kaplowitz, D.D.S., M.A., M.Ed and Marilyn Cortell, RDH, MS PennWell is an ADA CERP Recognized Provider Go Green, Go Online to take your course This course has been made possible through an unrestricted educational grant. The cost of this CE course is $59.00 for 4 CE credits. Cancellation/Refund Policy: Any participant who is not 100% satisfied with this course can request a full refund by contacting PennWell in writing. Educational Objectives in Europe in the early 1970s. It received FDA approval Upon completion of this course, the clinician will be able to in 1986 under the brand name PERIDEX® (Zila Phar- do the following: maceuticals) based on studies showing that it reduced 1. Explain the mechanism of action of chlorhexidine gingivitis by up to 41%. Soon after,1 PERIDEX®‚ was the gluconate. first mouthrinse to receive the ADA Seal of Acceptance. 2. Identify the unique property that allows for a Generic rinses have been available since 1994 and are prolonged effect. available from many different companies. In order to 3. Describe the clinical indications for use. qualify as a generic, the medication must prove to have 4. Understand the mechanism by which chlorhexidine may 80–120% of the bioavailability of the name brand to be cause extrinsic stain and the recommended home care considered bioequivalent. To date, there have been no strategies to reduce its occurrence.
    [Show full text]
  • Expression and Roles of Antimicrobial Peptides in Innate Defense Of
    Expression and Roles of Antimicrobial Peptides in Innate Defense of Airway Mucosa: Potential Implication in Cystic Fibrosis Carole Ayoub Moubareck, Dolla Karam Sarkis, Regina Geitani, Zhengzhong Xu, Lhousseine Touqui To cite this version: Carole Ayoub Moubareck, Dolla Karam Sarkis, Regina Geitani, Zhengzhong Xu, Lhousseine Touqui. Expression and Roles of Antimicrobial Peptides in Innate Defense of Airway Mucosa: Potential Impli- cation in Cystic Fibrosis. Frontiers in Immunology, Frontiers, 2020, 11, 10.3389/fimmu.2020.01198. hal-03145023 HAL Id: hal-03145023 https://hal.sorbonne-universite.fr/hal-03145023 Submitted on 18 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. REVIEW published: 30 June 2020 doi: 10.3389/fimmu.2020.01198 Expression and Roles of Antimicrobial Peptides in Innate Defense of Airway Mucosa: Potential Implication in Cystic Fibrosis Regina Geitani 1*†, Carole Ayoub Moubareck 1,2†, Zhengzhong Xu 3,4,5, Dolla Karam Sarkis 1 and Lhousseine Touqui 4,5* 1 Microbiology Laboratory, School of Pharmacy, Saint Joseph University, Beirut, Lebanon, 2 College of Natural and Health Sciences, Zayed University, Dubai, United Arab Emirates, 3 Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, 4 Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint Antoine (CRSA), Paris, France, 5 “Mucoviscidose and Bronchopathies Chroniques”, Pasteur Institute, Paris, France The treatment of respiratory infections is associated with the dissemination of antibiotic resistance in the community and clinical settings.
    [Show full text]
  • Antimicrobial-Associated Anaphylaxis Consequences on Infection Related Mortality and Prolonged Hospitalization
    Antimicrobial-Associated Anaphylaxis Consequences on Infection Related Mortality and Prolonged Hospitalization Laila Carolina Abu Esba ( [email protected] ) King Abdulaziz Medical City Faisal Aqeel Sehli King Abdulaziz Medical City Research Article Keywords: Allergy, Antimicrobial, Anaphylaxis, Antimicrobial stewardship Posted Date: February 24th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-243846/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/20 Abstract Background: Antimicrobial-associated anaphylaxis occurs at different rates and can lead to worsening infection-related outcomes, we sought to describe the incidence and complications of such episodes at a tertiary care hospital. Method: A retrospective cohort study was conducted between January 2016 and December 2019. Cases of antimicrobial-associated anaphylaxis were identied using the hospital’s electronic healthcare records. Outcomes included: mortality related to anaphylaxis, infection-related mortality, prolonged hospitalization and impact on antimicrobial prescribing. Results: The estimated rate of antimicrobial-associated anaphylaxis was 18.6 (95% CI: 11.8 –29.5) cases per 100,000 exposures. Prolonged hospitalization was seen in 52.4% of the cases, and major predictors for prolonged hospitalization were a switch to a more toxic antimicrobial (P 0.029) and switch to a broader spectrum antimicrobial (P 0.033). Conclusion: Implications from antimicrobial-associated anaphylaxis is beyond the episode itself, and can be associated with poor clinical outcomes such as infection-related mortality and prolonged hospitalization. 1. Introduction: Anaphylaxis as dened by the European Academy of Allergy and Clinical Immunology is a severe, life- threatening, generalized, or systemic hypersensitivity reaction [1].
    [Show full text]
  • Developing Strategies to Prevent Antimicrobial Resistance Marin H
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2006 The intensive care unit as a research laboratory: Developing strategies to prevent antimicrobial resistance Marin H. Kollef Washington University School of Medicine in St. Louis Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Kollef, Marin H., ,"The intensive care unit as a research laboratory: Developing strategies to prevent antimicrobial resistance." Surgical infections.7,2. 85-99. (2006). https://digitalcommons.wustl.edu/open_access_pubs/3172 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. SURGICAL INFECTIONS Volume 7, Number 2, 2006 © Mary Ann Liebert, Inc. Surgical Infection Society Twenty-Fifth Annual Altemeier Lecture The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance MARIN H. KOLLEF ABSTRACT Objective: To assemble the available clinical data on the prevention of antimicrobial resis- tance in the intensive care unit (ICU) setting. Data Source: A MEDLINE database search and references from identified articles were em- ployed to obtain the literature relating to the prevention of antimicrobial resistance in the ICU. Conclusions: The ICU presents a unique environment for the conduct of clinical research. The closed physical space with centralized patient management and efficient data recovery allows important clinical questions to be evaluated in a timely manner. Antimicrobial resis- tance has emerged as an important determinant of mortality for patients in the ICU.
    [Show full text]